IP Library › Granted Patent US 9,713,634
Granted Patent B2
US 9,713,634 · App. 15/041,841 · Granted Jul 25, 2017

Process for concentration of a polypeptide

Inventor: Stefan Nilsson (Lidingö, SE)
Assignee: Shire Pharmaceuticals Ireland Limited
A61K38/465A61K38/45A61K38/47C07K1/34C07K1/36C12Y205/01061C12Y301/06001C12Y302/01024C12Y302/01046C12Y301/06008
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,713,634
App. No.
15/041,841
Granted
Jul 25, 2017
Kind
B2
Abstract

The present invention comprises a method of concentrating a composition comprising a polypeptide of interest and the use of such concentrated composition for the treatment of diseases in mammals, in particular by subcutaneous injection.

Claims (11)

1. A method of treating metachromatic leukodystrophy comprising administering to a subject in need of treatment a composition comprising at least 25 mg/mL recombinant human arylsulfatase A (rhASA), wherein the amount of rhASA present as aggregates constitutes at least few and less than 5 w/w % of the total amount of rhASA in the composition.

2. The method of claim 1 , wherein the rhASA is present at a concentration no greater than 500 mg/mL.

3. The method of claim 1 , wherein the composition is an aqueous solution.

4. The method of claim 1 , wherein the composition further comprises a detergent.

5. The method of claim 1 , wherein the rhASA contains mannose-6-phosphate residues.

6. The method of claim 1 , wherein the rhASA comprises an amino acid sequence selected from the group consisting of

(i) an amino acid sequence as defined by any one of SEQ ID NOs: 18, 19, or 20; and

(ii) an amino acid sequence at least 95% identical to any one of SEQ ID NOs: 18, 19, or 20.

7. The method of claim 1 , wherein the rhASA is produced in mammalian host cells.

8. The method of claim 7 , wherein the mammalian host cells are human cells.

9. The method of claim 7 , wherein the mammalian host cells are Chinese Hamster Ovary (CHO) cells.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 15, 2021
From: SHIRE PHARMACEUTICALS IRELAND LIMITED
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 055936/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 12, 2016
From: NILSSON, STEFAN
To: SHIRE PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 038566/0868 →
Priority Claims (2)
DK 2006 00488 · Apr 4, 2006 · national
DK 2006 00922 · Jul 5, 2006 · national
Continuity (2)
Division 12295848
Related Publication 20160193304A1 · Jul 7, 2016